DOP2023000085A - Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados - Google Patents

Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados

Info

Publication number
DOP2023000085A
DOP2023000085A DO2023000085A DO2023000085A DOP2023000085A DO P2023000085 A DOP2023000085 A DO P2023000085A DO 2023000085 A DO2023000085 A DO 2023000085A DO 2023000085 A DO2023000085 A DO 2023000085A DO P2023000085 A DOP2023000085 A DO P2023000085A
Authority
DO
Dominican Republic
Prior art keywords
hair loss
deuterated
regimens
treatment
loss disorders
Prior art date
Application number
DO2023000085A
Other languages
English (en)
Spanish (es)
Inventor
V Cassella James
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of DOP2023000085A publication Critical patent/DOP2023000085A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DO2023000085A 2020-10-28 2023-04-28 Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados DOP2023000085A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US202163155637P 2021-03-02 2021-03-02
PCT/US2021/057123 WO2022094133A1 (en) 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
DOP2023000085A true DOP2023000085A (es) 2023-07-31

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000085A DOP2023000085A (es) 2020-10-28 2023-04-28 Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados

Country Status (14)

Country Link
US (1) US20230390292A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023553253A (cg-RX-API-DMAC7.html)
KR (1) KR20230093504A (cg-RX-API-DMAC7.html)
AU (1) AU2021372512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196551A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001201A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006808A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000085A (cg-RX-API-DMAC7.html)
IL (1) IL302401A (cg-RX-API-DMAC7.html)
JO (1) JOP20230090A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005027A (cg-RX-API-DMAC7.html)
PE (1) PE20231945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022094133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215520A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
MX2023005027A (es) 2023-07-31
AU2021372512A1 (en) 2023-06-22
JP2023553253A (ja) 2023-12-21
US20230390292A1 (en) 2023-12-07
PE20231945A1 (es) 2023-12-05
EP4236956A1 (en) 2023-09-06
CO2023006808A2 (es) 2023-09-08
CA3196551A1 (en) 2022-05-05
CL2023001201A1 (es) 2023-11-17
IL302401A (en) 2023-06-01
WO2022094133A9 (en) 2023-05-19
WO2022094133A1 (en) 2022-05-05
JOP20230090A1 (ar) 2023-04-27
KR20230093504A (ko) 2023-06-27

Similar Documents

Publication Publication Date Title
CO2023006808A2 (es) Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados
MX2018013347A (es) Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CL2021001951A1 (es) Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los desordenes asociados a la edad.
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
CL2020000911A1 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
DOP2024000146A (es) Inhibidores de parp7
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CL2025000970A1 (es) Compuesto inhibidor de parg
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
PE20241326A1 (es) Composiciones y tratamientos con nirogacestat
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
CL2022001102A1 (es) Métodos para el tratamiento de trastornos depresivos.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
DOP2025000009A (es) Inhibidores de acc novedosos
DOP2025000167A (es) Inhibidores de prmt5–mta
MX2024013641A (es) Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak
MX2025006279A (es) Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a
MX2025005720A (es) Inhibidores de la tirosina-cinasa 2 (tyk2)
AR133788A1 (es) Inhibidores de parp7
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
AR131842A1 (es) Métodos para tratar gliomas
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
CL2023000648A1 (es) Métodos para tratar enfermedades o afecciones mediadas por pde iv
MX2024003112A (es) Compuestos de beta-lactama o sales de los mismos para su uso en la prevencion o tratamiento de accion prolongada del trastorno del metabolismo de la glucosa.